Ozempic® and Weight Management: GLP-1 Mechanisms, Clinical Evidence and Medication Safety

What Is Ozempic® and Why Is It Associated with Weight Management?

Ozempic® is a prescription injectable medication containing semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA). It is primarily used in patients with type 2 diabetes who meet the approved indications, helping to manage blood glucose levels and associated health risks.

GLP-1 is a naturally occurring hormone released by the intestine. It plays a role in blood glucose regulation, gastric emptying and appetite signalling. By mimicking certain physiological actions of GLP-1, semaglutide stimulates insulin secretion when blood glucose levels are elevated while suppressing inappropriate glucagon secretion.

Because these mechanisms can also influence satiety and food intake, some individuals may experience weight reduction during blood glucose management. However, Ozempic® is not interchangeable with Wegovy®, a semaglutide product specifically approved for weight management. Although both contain the same active ingredient, their formulations, approved indications and prescribing considerations differ.

How Does Semaglutide Affect Appetite, Blood Glucose and Body Weight?

Semaglutide does more than simply suppress appetite. Its effects involve several interconnected physiological mechanisms.

1. Blood Glucose Regulation

Semaglutide influences insulin and glucagon secretion in a glucose-dependent manner, helping improve blood glucose control in some patients with type 2 diabetes. Individual responses depend on factors such as the patient’s medical condition, prescribed dose and concurrent medications.

2. Appetite and Satiety

GLP-1 receptor activity influences physiological signals associated with appetite and fullness. Some individuals may feel satisfied sooner during meals or experience a reduction in their usual food intake.

However, reduced appetite does not necessarily mean that nutritional requirements are being met. When food intake decreases significantly, adequate protein, essential nutrients and overall dietary quality remain important considerations.

3. Gastric Emptying

Semaglutide can delay gastric emptying, contributing to some of its effects on post-meal blood glucose regulation. This mechanism may also be associated with nausea, abdominal discomfort and other gastrointestinal symptoms.

For this reason, medical assessment of GLP-1 medications should consider not only blood glucose and body weight but also gastrointestinal health and individual medication tolerance.

What Does Clinical Research Tell Us About Semaglutide?

Semaglutide has been evaluated in several large clinical studies examining blood glucose management, changes in body weight, and cardiovascular and kidney-related outcomes in selected patient populations.

However, these studies differ in their formulations, doses and participant characteristics. Their findings should therefore not all be directly applied to Ozempic®.

Blood Glucose and Cardiovascular Health Research

The SUSTAIN clinical trial programme primarily evaluated semaglutide in patients with type 2 diabetes.

Among these studies, SUSTAIN-6 enrolled 3,297 patients with type 2 diabetes who were at elevated cardiovascular risk. The findings demonstrated a lower incidence of major cardiovascular events in the semaglutide group compared with the placebo group within this specific study population.

These results do not mean that every individual using semaglutide will experience the same cardiovascular benefits.

Kidney Health Research

The FLOW study, published in 2024, evaluated clinical outcomes associated with semaglutide in patients who had both type 2 diabetes and chronic kidney disease.

The study found a lower risk of the primary composite kidney-related outcome in the semaglutide group compared with placebo.

Importantly, the study involved patients with clearly defined medical conditions. Its results should not be generalized to individuals without diabetes or chronic kidney disease.

Research Related to Weight Management

The STEP 1 trial evaluated once-weekly semaglutide 2.4 mg alongside lifestyle intervention in adults with overweight or obesity.

Under the specified study conditions, participants receiving semaglutide achieved clinically meaningful average reductions in body weight.

However, STEP 1 investigated a weight-management dose of semaglutide. Its findings should not be presented as the expected weight-loss outcomes of individuals using Ozempic®.

Why Should Weight Management Consider More Than the Number on the Scale?

Body weight is an important health indicator, but it cannot independently reflect a person’s overall metabolic health.

Two individuals with the same weight and body mass index (BMI) may have different blood glucose levels, blood pressure, lipid profiles, muscle mass and cardiovascular risk.

A comprehensive medical approach to weight management should therefore consider several areas:

• Metabolic Health: Blood glucose, HbA1c, blood lipids, blood pressure and related indicators.

• Body Composition: Muscle mass, fat distribution and changes in waist circumference.

• Nutritional Status: Dietary quality, protein intake and overall nutritional adequacy.

• Lifestyle Factors: Physical activity, sleep and sustainable long-term health habits.

• Medical History: Existing conditions, current medications and relevant medical risks.

The American Diabetes Association’s 2026 guidance on overweight and obesity also emphasizes comprehensive clinical assessment, risk stratification and appropriate ongoing monitoring.

What Safety Risks Should Be Considered Before Using Ozempic®?

Ozempic® is a prescription medication and may not be appropriate for everyone seeking weight management.

Common adverse effects include nausea, vomiting, diarrhoea, constipation and abdominal pain. Some symptoms may occur when medication is first initiated or when the prescribed dose is adjusted.

In addition, a prescribing clinician should consider the following:

• A history of pancreatitis or gallbladder disease

• Significant gastrointestinal conditions

• Diabetic retinopathy

• Impaired kidney function and dehydration risk

• Increased hypoglycaemia risk when combined with certain other glucose-lowering medications

• Pregnancy, plans for pregnancy or breastfeeding

• Thyroid C-cell tumour-related warnings and contraindications stated in the applicable product information

• Upcoming procedures involving general anaesthesia or deep sedation

Individuals experiencing persistent severe abdominal pain, serious allergic reactions, an inability to maintain adequate hydration or sudden visual changes should seek prompt medical attention.

Patients should not independently change their prescribed dose, combine multiple semaglutide-containing products or discontinue medication without consulting their prescribing clinician.

How Does BMS Clinic Approach Personalised Medical Weight Management?

Body weight and metabolic health are influenced by a combination of physiological, medical and lifestyle factors. Medical management should therefore be based on each individual’s health circumstances.

BMS Clinic places importance on medical assessment and ongoing health monitoring, helping patients better understand their metabolic health and the suitability and limitations of different management options.

Assessment may include:

1. Reviewing medical history, changes in body weight and existing health conditions.

2. Evaluating blood glucose, HbA1c, blood pressure and other relevant metabolic indicators when appropriate.

3. Reviewing current medications, potential contraindications and associated risks.

4. Discussing dietary habits, physical activity and suitable medical management options.

5. Arranging ongoing health monitoring according to individual needs.

Whether prescription medication is appropriate, and which management approach should be considered, must be determined by a doctor based on approved indications, relevant product information and the patient’s individual health circumstances.

Key Takeaways

Semaglutide, the active ingredient in Ozempic®, acts through GLP-1-related mechanisms involved in blood glucose regulation and may also influence appetite and body weight.

Existing research provides clinical evidence for the use of semaglutide in specific patient populations. However, findings from different products, doses and study populations should not be treated as interchangeable.

For individuals exploring medical weight management, the priority should not simply be rapid weight reduction. An appropriate medical assessment can help identify metabolic risks, evaluate medication suitability and support informed decisions about long-term health management.